drugset / Trial / NCT03064763

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

NCT03064763

Phase 1 Completed 18 enrolled Amgen
NaSingle-groupOpen-labelOther

Summary

There are 2 fold of purposes for this study. 1 is to evaluate safety and tolerability and the other is to study the anti-tumor effects of talimogene laherparepvec in Japanese participants with unresectable stage IIIB-IV malignant melanoma.

Timeline

Start
2017-03-07
Primary completion
2020-08-03
Completion
2023-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified 4 ml Other

Indications